Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784106 | 1.00 | TAS1R3 (0.57) | TAS1R3TAS1R1TTRALBMAOA | |
| SCHEMBL10114288 | 0.86 | POLB (0.57) | TAS1R3TAS1R1POLBSMN1; SMN2CHRNA7 | |
| SCHEMBL30041235 | 0.86 | TDP1 (0.54) | TAS1R3TAS1R1TDP1POLBSMN1; SMN2 | |
| SCHEMBL701884 | 0.86 | TDP1 (0.54) | TAS1R3TAS1R1TDP1POLBSMN1; SMN2 | |
| SCHEMBL7103228 | 0.85 | TAS1R3 (0.56) | TAS1R3TAS1R1TTRALBMAOA | |
| SCHEMBL1680291 | 0.82 | ALDH1A1 (0.59) | TAS1R3TAS1R1POLBSMN1; SMN2CHRNA7 | |
| SCHEMBL27326884 | 0.82 | TAS1R3 (0.64) | TAS1R3TAS1R1TDP1POLBSMN1; SMN2 | |
| SCHEMBL14757935 | 0.80 | TAS1R3 (0.61) | TAS1R3TAS1R1POLBSMN1; SMN2CHRNA7 | |
| SCHEMBL20898200 | 0.79 | LCK (0.57) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL1121798 | 0.79 | TTR (0.64) | TTRALBMAOACNR1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| US-8389519-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-03-05 | — | — | US | claimed |
| US-8198275-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | claimed |
| JP-2011529057-A | — | — | 2011-12-01 | — | — | JP | claimed |
| WO-2010011570-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | WO | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025006293-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-6372757-B1 | OREXIN RECEPTORS FOR SLEEP DISORDERS AND EATING DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-16 | — | — | US | disclosed |
| EP-1075478-A1 | PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2001-02-14 | — | — | EP | disclosed |
| EP-1003737-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999058533-A1 | PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999009024-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-02-25 | — | — | WO | disclosed |
| US-5811427-A | FUNGICIDES; CONTROLLING PHYTOPATHOGENIC FUNGI PARTICULARLY OF THE CLASS OOMYCETES | ROHM AND HAAS COMPANY (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0816348-A1 | Heterocyclic n-acetonylbenzamides and their use as fungicides | ROHM AND HAAS COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | TAS1R3 1128/4885TAS1R1 1596/4885TTR 3228/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | TAS1R3 331/4885TAS1R1 159/4885TTR 2594/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | TAS1R3 2035/4885TAS1R1 2015/4885TTR 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.